Albany, NY -- (SBWIRE) -- 05/28/2020 -- Hepatocellular Carcinoma Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Hepatocellular Carcinoma Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total Hepatocellular Carcinoma incident population in the G8 was 460,992 in 2017.
2. Japan had 38,261 HCC incident cases in 2017.
3. Males account for the highest number of incident patients with Hepatocellular Carcinoma.

Key benefits of the report
1. Hepatocellular Carcinoma market report covers a descriptive overview and comprehensive insight of the HCC epidemiology and Hepatocellular Carcinoma market in the United States, EU5 (Germany, Spain, France, Italy, UK), Japan and China.
2. HCC market report provides insights into the current and emerging therapies.
3. Hepatocellular Carcinoma market report provides a global historical and forecasted market covering drug outreach.
4. HCC market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatocellular Carcinoma market.

Request for sample pages

"Hepatocellular Carcinoma Market Size in the G8 was 709.19 Million in 2017".

Hepatocellular Carcinoma is a dreadful condition. Currently, there are few approved drugs for unresectable hepatocellular carcinoma, but researchers are actively engaged in finding the cure by targeting other pathways. One hope is that by using combinational therapies, a person with HCC will be able to live a better life.

Generally, Hepatocellular Carcinoma treatment patients is recommended at early-stage HCC and may not be recommended for the patients with later stages of the disease. Currently, the major treatment options of Hepatocellular Carcinoma are:

Hepatic Resection is the treatment for hepatocellular carcinoma in patients without cirrhosis, in whom major resections could be done without life-threatening complications. In patients with decompensated cirrhosis, hepatic Resection is formally contraindicated, and liver transplantation should be considered. Patients with compensated cirrhosis should be carefully evaluated to avoid treatment-related complications and achieve long-term survival.

Theoretically, liver transplantation is the best treatment option since it might simultaneously cure the tumour and the underlying cirrhosis. The likelihood of patient survival after transplantation remains the essential criterion to indicate Hepatocellular Carcinoma treatment. Other than this, Image-guided transcatheter tumour therapies aim to induce tumour necrosis and are based on the predominantly arterial vascularization of hepatocellular carcinoma compared with the surrounding liver parenchyma.

Recent developments in drug portfolio have impacted the overall HCC treatment regimen. Sorafenib and Miripla (Japan) were the first approved therapy and had a 10-year long hold on the market. Now, Lenvatinib has also been approved as first-line therapy. Furthermore, Opdivo, Regorefinib, Keytruda, Cyramza, and Carbometyx have opted as second-line therapies along with some off-label Hepatocellular Carcinoma treatment option.

The launch of the emerging therapies is expected to significantly impact Hepatocellular Carcinoma treatment scenario in the upcoming years:-
Drugs covered
1. ATG-008
2. SHR-1210
And many others

The key players in Hepatocellular Carcinoma market are:
1. Antengene Therapeutics
2. Jiangsu HengRui Medicine
And many others

Table of contents
1. Key Insights
2. Hepatocellular Carcinoma Market Overview at a Glance
3. HCC Disease Background and Overview
4. Hepatocellular Carcinoma Epidemiology and Patient Population
5. Key Findings
6. HCC Population and Forecast Parameters
7. Country Wise-HCC Epidemiology
7.1. United States
7.2. EU5 Countries
7.3. Germany
7.4. France
7.5. Italy
7.6. Spain
7.7. United Kingdom
7.8. Japan
7.9. China
8. Treatment Practices
9. Unmet Needs
10. Hepatocellular Carcinoma Marketed Drug Analysis
10.1. Nexavar: Bayer HealthCare
10.2. Miripla: Sumitomo Dainippon Pharma
10.3. Opdivo: Bristol-Myers Squibb
11. Hepatocellular Carcinoma Emerging Therapies
12. HCC Emerging Drugs Analysis
12.1. ATG-008: Antengene Therapeutics
12.2. SHR-1210: Jiangsu HengRui Medicine
13. Failure in Phase III Clinical trials for Hepatocellular Carcinoma
14. Hepatocellular Carcinoma G8 Countries Market Analysis
15. Key Findings
15.1. Total Market Size of Hepatocellular Carcinoma in G8 Countries
15.2. G8 Countries Market Size of HCC by Line of Therapies
15.3. G8 Countries Market Size of HCC by Therapies
16. Hepatocellular Carcinoma Market Outlook by Country
16.1. The United States: Market Outlook
16.2. EU-5 Countries: Market Outlook
16.3. Germany
16.4. France
16.5. Italy
16.6. Spain
16.7. United Kingdom
16.8. Japan: Market Outlook
16.9. China: Market Outlook
17. Market Drivers
18. Market Barriers
19. Appendix
20. Hepatocellular Carcinoma Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight